Novartis develops breast cancer targeted drug ribociclib

Ribociclib , commonly known as Kisqali, is a drug carefully developed and produced by Novartis, a world-renowned Swiss pharmaceutical company. Novartis, as the world's leading pharmaceutical and biotechnology company, has been committed to providing innovative medical and health solutions to patients around the world.

The development story of ribociclib can be traced back to the end of the 20th century to the beginning of the 21st century, when scientists became very interested in cyclin-dependent kinases (CDKs). They found that CDK4 and CDK6 play key roles in the regulation of the cell cycle, and inhibiting these kinases can effectively curb the growth of cancer cells. Based on this discovery, Novartis decided to develop an inhibitor targeting CDK4/6 with its strong R&D background. After years of efforts, ribociclib (ribociclib) was finally born.

In order to ensure the safety and effectiveness of Ribociclib (Riboxiclib) , Novartis conducted comprehensive clinical trials from Phase I to Phase III. Among them, the high-profile MONALEESA series of trials verified ribociclib (ribociclib) in the treatment of specific types of breast cancer——That is, significant efficacy in hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. Trial data show that when ribociclib (ribociclib) is used in combination with an aromatase inhibitor, it can significantly extend the progression-free survival of patients.

Based on this series of convincing clinical data, ribociclib (ribociclib) received marketing approval from the U.S. Food and Drug Administration (FDA) in March 2017. Since then, it has obtained marketing approval in many countries and regions around the world, and has quickly become a shining star in the field of breast cancer treatment.

The successful launch of Ribociclib not only adds to Novartis's success in the field of anti-cancer drug research and development, but also brings new treatment options to breast cancer patients around the world. The achievement of this result undoubtedly demonstrates Novartis' outstanding strength in all aspects of scientific research, clinical trials, and marketing. Riboxiclib (Riboxiclib), as an outstanding representative of Novartis Pharmaceuticals, is winning widespread praise from patients and doctors around the world for its unique efficacy and safety.